News | Radial Access | July 13, 2016

Study Affirms Radial Access as Default Approach for Inserting Stents

Results show reduced bleeding complications, death rates with radial over femoral access

radial access, inserting stents, JACC Cardiovascular Interventions study

July 13, 2016 — A new study in JACC: Cardiovascular Interventions supports access through the wrist, or radial access, as the default approach when inserting stents to restore blood flow in heart disease patients. Study results show radial access has fewer complications than access through the groin, or femoral access.

Researchers looked at 24 studies, enrolling 22,843 participants to conduct a comprehensive meta-analysis across the spectrum of heart disease. They determined there was "strong to very strong" evidence that major bleeding and vascular complications were reduced and "moderate to strong" evidence that all-cause death rates were reduced when using radial access versus femoral access.

Researchers concluded that the benefits of radial access support it being the default approach for all heart disease patients needing this procedure.

Radial access is a newer procedure and it involves a longer learning curve to develop the technical skills necessary. However, JACC: Cardiovascular Interventions Editor-in-Chief Spencer King, M.D., MACC, said, “As radial access is increasingly adopted, the benefits seen in trials have been weighed against the learning curve necessary for some operators. This most complete analysis of the value of radial access may convince some doubters to switch.”

For more information: www.interventions.onlinejacc.org


Related Content

Feature | Cath Lab | Kyle Hardner

Since receiving FDA approval in 2016, intravascular lithotripsy (IVL) systems have grown in popularity among ...

Home November 14, 2025
Home
News | Cath Lab

Nov. 11, 2025 — FastWave Medical has successfully completed enrollment in its 30-patient coronary feasibility study and ...

Home November 13, 2025
Home
News | Cath Lab

Oct. 28, 2025 — Results from the first-of-its-kind randomized PROCTOR trial found that a strategy of saphenous vein ...

Home November 04, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65 ...

Home October 29, 2025
Home
News | Cath Lab

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical ...

Home October 28, 2025
Home
News | Cath Lab

Oct. 22, 2025 — Heartflow, Inc. has introduced Heartflow PCI Navigator, the newest addition to the Heartflow One ...

Home October 23, 2025
Home
News | Cath Lab

Oct. 15, 2025 — Stereotaxis recently announced it has obtained CE Mark in Europe and submitted a 510(k) application to ...

Home October 16, 2025
Home
News | Cath Lab

Oct. 7, 2025 — Medtronic has announced the full distribution of the Neuroguard IEP System (Neuroguard) after a ...

Home October 07, 2025
Home
News | Cath Lab

Sept. 22, 2025 — Nicklaus Children's Heart Institute in Miami, Florida, is now offering bedside transcatheter patent ...

Home September 23, 2025
Home
Subscribe Now